Hacibekiroglu, IlhanKodaz, HilmiErdogan, BulentTurkmen, EsmaEsenkaya, AsimOnal, YilmazUzunoglu, Sernaz2024-06-122024-06-1220152049-94502049-9469https://doi.org/10.3892/mco.2015.592https://hdl.handle.net/20.500.14551/20552The aim of this study was to retrospectively compare the efficacy and toxicity of the oxaliplatin + 5-fluorouracil (5-FU) + leucovorin (LV) regimen [modified (m) FOLFOX-6] with that of the docetaxel + cisplatin + 5-FU regimen (DCF) in patients with advanced gastric cancer (AGC). A total of 72 patients received DCF (75 mg/m(2) docetaxel and 75 mg/m(2) cisplatin on day 1 and 750 mg/m(2) 5-FU on days 1-5) every 21 days, whereas 54 patients received mFOLFOX-6 (85 mg/m(2) oxaliplatin and 400 mg/m(2) LV as a 2-h infusion, followed by a 5-FU bolus of 400 mg/m(2) and 2,400 mg/m(2) 5-FU as a 46-h continuous infusion) every 14 days. In the DCF arm, 55 (76.4%) of the patients received prophylactic granulocyte colony-stimulating factor (G-CSF), 48-72 h following completion of chemotherapy. The median follow-up of the study was 12.1 months. The overall response rate (ORR) was 37.0% for mFOLFOX-6 and 40.3% for DCF (P=0.72). The median time to progression was 6.5 and 6.2 months in the mFOLFOX-6 and DCF arms, respectively (P=0.70). The median overall survival was 11.4 and 13.5 months in the mFOLFOX-6 and DCF arms, respectively (P=0.72). The rates of hematological toxicity did not differ between the two arms. However, in the subgroup analysis, grade 3-4 neutropenia and febrile neutropenia were significantly more common among patients who had not received G-CSF prophylaxis in the DCF arm. The incidence of grade 3-4 nausea/vomiting and diarrhea were significantly higher in the DCF arm. In conclusion, the present study demon-strated that the efficacy of the mFOLFOX-6 regimen was comparable to that of the DCF regimen in AGC patients. In addition, the benefit of G-CSF prophylaxis in conjunction with the DCF regimen was demonstrated.en10.3892/mco.2015.592info:eu-repo/semantics/openAccessDocetaxel + Cisplatin + 5-Fluorouracil RegimenOxaliplatin + 5-Fluorouracil + Leucovorin RegimenGastric CancerFirst-LineColony-Stimulating FactorPhase-Ii TrialFolinic AcidInfusional FluorouracilFebrile NeutropeniaWeekly OxaliplatinSupportive CarePlus CisplatinBreast-CancerChemotherapyArticle3511601164N/AWOS:00045315750003526623070